MarketVIEW Travel & Endemic Vaccines  ·  Updated Summer 2026

Chikungunya Vaccines
Commercial Forecast

2025 was the worst year on record for chikungunya - a global resurgence, two newly licensed vaccines, and a safety crisis that removed the first-to-market product from the United States. This is the independent commercial assessment of the opportunity: travel, endemic and outbreak-response markets modelled across a landscape reset by the IXCHIQ suspension and the rise of VIMKUNYA. It draws on VacZine Analytics' long-standing, independent authority in the travel and infectious-disease vaccine markets.

2025 Global Resurgence 2 Licensed Vaccines IXCHIQ Suspension Assessed Travel & Endemic Markets VLP vs Live-Attenuated
Product catalogue
VAMV005
Updated Summer 2026 edition

Format
PDF + Excel model
Coverage
Travel, endemic, outbreak
Vaccines assessed
IXCHIQ & VIMKUNYA
Markets
Public & private
Approach
Scenario-based
Base year
2026
Availability
Syndicated / bespoke
445k
Reported CHIKV cases in 2025
(Jan-Sep, 40 countries, WHO)
2
Licensed vaccines
IXCHIQ & VIMKUNYA
~40%
Cases progressing to
chronic arthralgia
Aug 2025
IXCHIQ US licence
suspended - market reset
Disease background

Why chikungunya has become a vaccine priority

Chikungunya has moved from a neglected tropical curiosity to a globally expanding public-health threat. Understanding the virus, its vector and its chronic burden is central to understanding where - and to whom - a vaccine can be sold.

Peer-reviewed & WHO 2025 data

Pathogen overview - Chikungunya virus (CHIKV)

Chikungunya virus is a mosquito-borne alphavirus of the family Togaviridae, first identified in Tanzania in 1952. It is transmitted to humans principally by Aedes aegypti and Aedes albopictus mosquitoes - the same day-biting vectors responsible for dengue and Zika. The name derives from the Kimakonde word meaning "to become contorted", describing the stooped posture of patients suffering the severe joint pain that characterises the disease.

Acute infection presents with abrupt high fever and intense, frequently debilitating polyarthralgia, often accompanied by rash, myalgia and headache. While acute mortality is low, the defining feature of chikungunya is its chronic burden: a substantial proportion of patients - up to around 40% in some cohorts - develop persistent or relapsing arthralgia lasting months to years, driving long-term disability, lost productivity and healthcare cost. It is this chronic sequela, rather than acute lethality, that underpins the health-economic case for vaccination.

The epidemiology has changed profoundly. A major 2004-2006 epidemic in the Indian Ocean (notably La Reunion, where roughly a third of the population was infected) was followed by introduction to the Americas via the Caribbean in 2013, seeding an epidemic of well over one million suspected cases across the region. The global spread of Aedes albopictus has since extended autochthonous transmission risk into temperate zones, including autochthonous outbreaks in southern Europe.

2025 marked an unprecedented resurgence. Between January and September 2025, WHO recorded 445,271 suspected and confirmed cases and 155 deaths across 40 countries. La Reunion alone reported 54,517 confirmed cases and 40 deaths - its first major transmission since 2005-06 - while Guangdong Province, China, experienced its largest ever outbreak (16,452+ cases from July 2025). On 22 July 2025 WHO issued a public warning that billions of people now live in areas at risk.

2025 WHO: 445,271 cases  |  155 deaths  |  40 countries (Jan-Sep 2025)  |  billions at risk
Product & competitor landscape

Two licensed vaccines - and a market in flux

Chikungunya went from having no vaccine to two licensed products in barely 15 months. Then, in 2025, the first-to-market product was suspended in the United States. The competitive picture has rarely moved faster - and the VacZine Analytics model tracks every scenario.

  • ValnevaUS licence suspended
    IXCHIQ (VLA1553) Approved 2023
    Single-dose, live-attenuated vaccine - the first chikungunya vaccine ever licensed (FDA Nov 2023; EU 2024, incl. ages 12-17; UK MHRA 2025, ages 18-59). In 2025 a serious safety signal in older adults triggered an FDA/CDC pause; the US biologics licence was suspended in August 2025 and Valneva withdrew its US BLA and IND in January 2026. The EMA has temporarily restricted use in adults 65+ pending review; contraindicated in immunocompromised individuals. In its August 2026 half-year results Valneva confirmed it is re-evaluating IXCHIQ's commercial strategy, shifting focus away from the travel market and toward endemic-country use after weaker-than-anticipated sales (H1 2026 one-off charges of €14.2m for contract termination and inventory write-down); a Brazilian Ministry of Health/Instituto Butantan pilot campaign (Feb-Oct 2026) ultimately vaccinated nearly 80,000 adults aged 18-59, data that will underpin ongoing post-marketing effectiveness and safety studies. On 7 October 2026 the UK's MHRA went further and revoked IXCHIQ's UK marketing authorisation entirely, following a further CHM benefit-risk review of pre-existing safety data; Valneva stated the move was not linked to any newly identified safety signal, and that EU, Canadian, Brazilian and other licences are unaffected. Separately in the EU, a periodic safety-update review led the EMA's CHMP to recommend (25 June 2026) narrowing IXCHIQ's authorised indication from general use in those aged 12 and over to use only in people aged 12 and over who are at high risk of acquiring chikungunya infection; the updated EU product information took effect in August 2026. On 10 November 2026 Valneva reported new long-term data from its VLA1553-303 follow-up study: 94% of 221 evaluable healthy adults retained a neutralising-antibody seroresponse five years after a single IXCHIQ dose, with persistence in those aged 65 and over comparable to adults aged 18-64 - durability the company is positioning as a differentiator for endemic and low- and middle-income markets.
  • Bavarian NordicMarket leader (US)
    VIMKUNYA (CHIKV VLP, formerly PXVX0317) Approved 2025
    Single-dose recombinant virus-like-particle vaccine (originated at Emergent BioSolutions). FDA approved 14 Feb 2025 for ages 12+ - the first VLP chikungunya vaccine - with a positive EU CHMP opinion (Jan 2025) and launch across key markets in H1 2025. Phase 3 data showed up to 97.8% of recipients seroconverting by day 21. Following the IXCHIQ suspension it is effectively the sole actively marketed chikungunya vaccine in the US. Regulatory reach continues to widen: Health Canada approved VIMKUNYA in June 2026, Bavarian Nordic's fifth global authorisation after the US, EU, UK and Switzerland. In July 2026 distribution partner Eurofarma submitted VIMKUNYA to Brazil's Anvisa for approval in ages 12+ - a first step into the endemic market that accounted for over half of 2025's global chikungunya caseload.
  • Bharat Biotech / Ind-CEPIClinical
    BBV87 (inactivated)
    Whole-virion inactivated candidate advanced with international (CEPI/IVI) support, positioned for endemic and lower-income markets. Representative of a second wave of candidates aimed at affordability and endemic-country programmes.
  • Earlier-stage pipelineVarious
    Measles-vectored, mRNA and next-generation candidates
    Including the measles-vectored MV-CHIK programme and mRNA approaches. The report reviews the full pipeline and its relevance to second-generation positioning, particularly for older adults and endemic populations underserved by the current products.
Market reset
Aug 2025

The IXCHIQ US licence suspension is the defining commercial event in this market. After serious adverse events in older adults - including deaths - the FDA suspended the biologics licence in August 2025, and Valneva withdrew its US applications in January 2026. Overnight this reset the competitive landscape in the world's most valuable vaccine market, leaving VIMKUNYA as the sole marketed option in the US while EMA restrictions reshaped the ex-US picture. The VacZine Analytics model quantifies the commercial consequences under multiple scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW chikungunya analysis spans disease burden, target-population rationale, the two licensed vaccine profiles and scenario-based revenue forecasting across the travel, endemic and outbreak-response markets.

Travel market forecast

Traveller demand from high-income source markets to endemic destinations, modelled across travel-clinic, military and expatriate channels with uptake and pricing assumptions.

Endemic & outbreak-response model

Separate scenarios for endemic-country routine use and outbreak/stockpile procurement, informed by the 2025 resurgence across the Americas, Indian Ocean and Asia.

Competitor & pipeline review

Head-to-head assessment of IXCHIQ (live-attenuated) and VIMKUNYA (VLP) - profiles, labels, age ranges, safety and the commercial implications of the IXCHIQ suspension.

Scenario-based revenue forecasts

Base, upside and conservative scenarios, with explicit assumptions on approvals, safety-driven restrictions, uptake and pricing across public and private channels.

Disease burden & epidemiology

Updated epidemiology using the WHO 2025 outbreak data, historical Indian Ocean and Americas epidemics, vector expansion and the chronic-arthralgia burden.

Pricing & market access

Pricing rationale and access dynamics across travel clinics, national travel-health recommendations, military procurement and endemic/outbreak public programmes.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Target populationGeographyMarket typeVaccine profileRevenue scenario
Travellers to endemic regionsHI source marketsPrivate / travel clinicSingle-dose pre-travelModelled
Military & expatriatesGlobalInstitutionalSingle-doseModelled
Endemic-country routineAmericas / AsiaPublic programmeRoutine / risk-basedModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseGlobalAllAll profiles$███m
Full model in the licensed workbook
Travel · endemic · outbreak · 3 scenarios · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model - built for decision-makers who need the full picture on the chikungunya vaccine opportunity.

  • Executive presentation (PDF) - disease background, epidemiology, the 2025 resurgence, vaccine profiles and full commercial assessment with supporting narrative and references
  • Interactive MS-Excel forecast model - volume and revenue outputs with scenario toggles, target-population breakdowns and pricing assumptions across public and private markets
  • Scenario-based commercial forecasts - base, upside and conservative cases for travel, endemic and outbreak-response segments, with explicit assumptions
  • Competitor intelligence - IXCHIQ vs VIMKUNYA head-to-head, the US licence suspension and its commercial consequences, and EMA/MHRA restriction analysis
  • Updated epidemiology module - WHO 2025 outbreak data, La Reunion and China outbreaks, historical Americas and Indian Ocean epidemics and vector expansion
  • Travel, endemic & outbreak segmentation - traveller demand, military/expatriate channels, endemic-country programmes and stockpile/outbreak procurement
Target audience

Built for organisations weighing the chikungunya opportunity

Most valuable to teams evaluating the chikungunya market against their own pipeline, BD ambitions or investment thesis - particularly in the context of the IXCHIQ suspension and VIMKUNYA's rise.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for chikungunya candidates at any stage.

Corporate strategy & BD

Validate the market size and structure post-IXCHIQ suspension, and understand the competitive landscape around VIMKUNYA.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on chikungunya and travel-vaccine assets.

Travel & public health

Demand modelling for travel-health providers and endemic/outbreak public programmes and stockpiles.

Researchers & academia

Comprehensive epidemiology, resistance to control and the vaccine landscape for grant and translational planning.

Market access & policy

Pricing benchmarks, travel-health recommendation dynamics and procurement feasibility across markets.

About this analysis · VAMV005

VacZine Analytics has tracked the chikungunya vaccine opportunity since the earliest editions of this report. It is one of our most unique and most frequently visited analyses - combining a rigorous epidemiological and clinical review with an independently constructed commercial model spanning the travel, endemic and outbreak-response markets that most forecasts treat only in isolation. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis.

The travel component was refreshed in our 2023 travel-vaccines segment report and is being updated for summer 2026 to reflect the VIMKUNYA launch, the IXCHIQ US licence suspension and subsequent EMA/MHRA restrictions, and the exceptional 2025 global resurgence documented by WHO. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV005 · Syndicated & bespoke

Syndicate the report - or commission the answer you need

Register your interest to help shape and secure the full syndicated MarketVIEW edition, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc chikungunya analysis - a briefing call is included on request.